| Customization: | Available |
|---|---|
| CAS No.: | 540737-29-9 |
| Formula: | C16h20n6o.C6h8o7 |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product name: Tofacitinib citrate
CAS No: 540737-29-9
Tofacitinib citrate is an oral Janus kinase (JAK) inhibitor used in the treatment of autoimmune diseases. It selectively inhibits JAK1 and JAK3, enzymes involved in the signaling pathways of various pro-inflammatory cytokines. By blocking these enzymes, tofacitinib reduces inflammation and modulates the immune system. This medication is primarily used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib citrate is the citrate salt form, which improves its solubility and absorption, allowing effective systemic distribution.
Application and Effect
Tofacitinib citrate is widely prescribed for the management of autoimmune and inflammatory disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC). In rheumatoid arthritis, it helps to reduce symptoms such as joint pain, swelling, and stiffness, and it slows the progression of joint damage by targeting the immune system's inflammatory response. Tofacitinib is particularly beneficial for patients who have not responded adequately to traditional disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) inhibitors. The drug works by inhibiting Janus kinases (JAKs), which play a critical role in the signaling of several cytokines involved in immune responses. This inhibition reduces the activation of immune cells that contribute to inflammation, offering relief from symptoms of inflammation and tissue damage. By modulating the immune system, tofacitinib also helps to reduce the severity of flare-ups in autoimmune diseases. Tofacitinib citrate is taken orally and is often used in combination with other medications. It provides a convenient alternative to biologic therapies, which typically require injection or infusion. The medication has been shown to improve physical function, reduce the need for steroids, and maintain disease control in patients with moderate to severe disease. However, as with other immunosuppressive agents, it carries risks such as increased susceptibility to infections, and regular monitoring of blood counts and liver function is recommended during treatment.
Specifications:
| Composition | C16H20N6O.C6H8O7 |
| Assay | 99% |
| Appearance | White to beige powder |
| CAS No. | 540737-29-9 |
| Packing | Small and bulk |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |
){kind=link}